Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (241-250 of 252) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 TrialJustin Ferdinandus, Helen Kaul, Alexander Fosså, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
Lancet (London, England)|October 25, 2017
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupPeter Borchmann, Helen Goergen, Carsten Kobe, et al.
Lancet (London, England)|December 26, 2014
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trialKarolin Behringer, Helen Goergen, Felicitas Hitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell LymphomaRichard T Maziarz, Michael R Bishop, Constantine S Tam, et al.
Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.
The New England Journal of Medicine|December 14, 2021
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R Bishop, Michael Dickinson, Duncan Purtill, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER StudyLorenz Thurner, Marita Ziepert, Christian Berdel, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Cancer Cell|June 13, 2025
CSF1R<sup>+</sup> myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphomaDavid Stahl, Philipp Gödel, Hyatt Balke-Want, et al.
Pageof 26

Showing results (241-250 of 252) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 TrialJustin Ferdinandus, Helen Kaul, Alexander Fosså, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
Lancet (London, England)|October 25, 2017
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupPeter Borchmann, Helen Goergen, Carsten Kobe, et al.
Lancet (London, England)|December 26, 2014
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trialKarolin Behringer, Helen Goergen, Felicitas Hitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell LymphomaRichard T Maziarz, Michael R Bishop, Constantine S Tam, et al.
Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.
The New England Journal of Medicine|December 14, 2021
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R Bishop, Michael Dickinson, Duncan Purtill, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER StudyLorenz Thurner, Marita Ziepert, Christian Berdel, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Cancer Cell|June 13, 2025
CSF1R<sup>+</sup> myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphomaDavid Stahl, Philipp Gödel, Hyatt Balke-Want, et al.
Pageof 26